You are here
Investigational New Drug (IND) & Investigational Device Exemptions (IDE) Applications Preparation and Submission, and Conducting FDA Meetings (Philadelphia, PA, United States - June 20-21, 2019)
DUBLIN, May 15, 2019 /PRNewswire/ -- The "Investigational New Drug (IND) & Investigational Device Exemptions (IDE) Applications Preparation and Submission, and Conducting FDA Meetings: 2-Day In-Person Seminar" conference has been added to ResearchAndMarkets.com's offering.
Submissions to a regulatory agency involve more than just writing of applications. They also encompass strategy, editing, publishing and systematic tracking of key information. Through formal lectures, case studies, and hands-on exercises, new and experienced regulatory professionals will learn how to interpret regulations and guidance documents to produce submissions that comply with the requirements and are clear to the reviewers.
In this practical course, which is designed to help participants to acquire the knowledge and insight needed to understand and begin to construct core U.S. drug and biologics submissions, including Investigational New Drug (IND), and Investigational Device Exemptions (IDE) applications. Participants also will gain experience with tools that help manage timelines and sections needed from contributors.
- Identify the required regulations and guidance documents for drug and device submissions
- Use regulations and guidance documents to outline and construct drug and device submissions
- Formulate a working knowledge of regulatory submissions, publishing, and style guides
- Create checklists that encompass timelines and sections needed from contributors
- Contents of IND and IDE
- Regulatory requirements for IND and IDE application process
- Submissions to IND or IDE to the FDA
- Establishing communications with FDA
- Type of FDA meetings
- Amendments to IND and IDE applications
- Progress reports for IND and IDE
Who Should Attend:
- Project Managers
- Clinical Research Associates
- Data Managers
- Project Team Leaders with limited direct regulatory experience
- Grant Administrators
- Regulatory Associates
- Quality Assurance specialists
- Manufacturing, Clinical, and Pre-Clinical Personnel which will be contributing to the IND/IDE or want to learn more about IND/IDE applications process
Registration. Meet & Greet.
FDA Division Information.
Overview of Submissions Process and Assembling Application: creating the Table of Contents, timing of submission/timelines, contributions from other departments, editing, style guides, templates, supportive documents, QA for the submission.
Overview of Investigational Drug Application (IND) format and contents.
Preparation for IND Submission. Routine IND Submissions: Assembling clinical, non-Clinical, CMC, etc. data for FDA drug applications.
Tracking the Submissions: Creating the index history an issues log.
Preparation for meetings with FDA.
Types of FDA Meetings: Type A, B and C;
Pre-IND, Phase I, Phase II, End of Phase II, requesting the meeting, preparing the meeting package, meeting minutes.
Registration, Meet & Greet.
IND Maintenance: Annual Reports, Safety Reports and Investigator Brochure updates, protocol and informational amendments, Investigator change notifications.
Special situations for IND submissions: Fast track, orphan drug designation, special protocol assessment.
Overview of device classes, significant and non-significant risk determinations.
Investigational Device Exemption (IDE) content and application process, regulatory requirements and best practices.
Strategies for new device application submissions with FDA depending on the class of the device.
IDE maintenance: supplements, amendments, safety and annual reports.
Additional types of device studies: Extended access programs and Humanitarian Device Exemption (HUD).
Group work on the case study.
Case Study: Investigational New Drug Application Preparation.
Discussion of the Case study and Closing remarks
For more information about this conference visit https://www.researchandmarkets.com/r/pn274b
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/investigational-new-drug-ind--investigational-device-exemptions-ide-applications-preparation-and-submission-and-conducting-fda-meetings-philadelphia-pa-united-states---june-20-21-2019-300849748.html
SOURCE Research and Markets